A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Status:
Not yet recruiting

Trial end date:
2024-05-21

Target enrollment:

Participant gender:

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in Myeloid tumor patients.

Phase 1

Innovent Biologics (Suzhou) Co. Ltd.

Azacitidine
Decitabine